For an adult with knee osteoarthritis who continues to have pain despite acetaminophen, NSAIDs, physical therapy, and prior intra‑articular corticosteroid injections, which injection is recommended?

Injection for Knee Osteoarthritis After Failed Conservative Treatment

For a patient with knee osteoarthritis who has failed acetaminophen, NSAIDs, physical therapy, and prior corticosteroid injections, repeat intra-articular corticosteroid injection remains the recommended option, though you should strongly consider referral for joint replacement surgery at this stage.

Primary Recommendation: Repeat Corticosteroid Injection

The most recent AAOS 2022 guideline provides the strongest evidence supporting intra-articular corticosteroid injections with 19 high-quality and 6 moderate-quality studies demonstrating pain reduction and improved function 1. While the duration of benefit is typically limited to 3 months, this remains the most evidence-based injectable option available 1.

Key Points About Corticosteroid Re-injection:

• Efficacy: Provides significant pain relief for moderate to severe knee OA pain 2, 1
• Safety: Generally safe when used appropriately, though avoid more than 3-4 injections per year in the same joint 3
• Timing: The decision to reinject should consider benefits from previous injections and individual factors 3
• Formulation: Triamcinolone hexacetonide offers advantages over triamcinolone acetonide and should be preferred when available 4

Alternative Injectable Options (Listed in Order of Evidence Quality)

Platelet-Rich Plasma (PRP)

The 2022 AAOS guideline identifies PRP as an alternative with 2 high-quality and 1 moderate-quality study supporting reduced pain and improved function 1. However, critical caveats apply:

• Works poorly in severe knee OA (worse treatment response) 1
• Cost and safety concerns remain 1
• The 2020 ACR guideline strongly recommends against PRP due to heterogeneity and lack of standardization in preparations 5

Clinical Decision Point: Only consider PRP if the patient has mild-to-moderate OA, can afford out-of-pocket costs, and understands the conflicting evidence.

Hyaluronic Acid (HA)

This option faces the most controversy in current guidelines:

• NICE 2008: Explicitly states "intra-articular hyaluronan injections are not recommended" 2
• AAOS 2022: Recommends against routine use - 17 high-quality and 11 moderate-quality studies showed inconsistent results, with a number needed to treat of 17 1
• ACR 2020: Conditionally recommends against HA, noting that benefit was only seen in studies with high risk of bias 5

However, the ACR acknowledges that in shared decision-making, HA may be considered "when other alternatives have been exhausted or failed to provide satisfactory benefit" 5. This describes your patient's situation.

Clinical Decision Point: HA can be discussed as a last-resort injectable option before surgery, but patients must understand the limited evidence of benefit. The conditional recommendation against is consistent with using it when corticosteroids and other options have failed 5.

What NOT to Inject

Strongly Recommended Against:

• Botulinum toxin: Limited trials suggest lack of efficacy 5
• Prolotherapy: Small effect sizes with substantial variability 5

Critical Consideration: Surgical Referral

At this stage of treatment failure, you should be actively considering joint replacement referral 2. The NICE guideline specifically states: "Consider referral for joint replacement surgery for people with osteoarthritis who have joint symptoms (pain, stiffness, and reduced function) that substantially affect their quality of life and are refractory to non-surgical treatment" 2.

Referral Criteria:

• Patient has received core treatments (exercise, weight loss if applicable, NSAIDs, physical therapy) ✓
• Patient has tried intra-articular corticosteroids ✓
• Symptoms substantially affect quality of life
• Referral should occur before prolonged and established functional limitation develops 2

Practical Algorithm

For your patient who has failed multiple conservative treatments:

1. First-line: Repeat intra-articular corticosteroid injection (preferably triamcinolone hexacetonide)

   • Expect 3 months of benefit
   • Safe to repeat if >3 months since last injection
   • Limit to 3-4 injections per year in same joint

2. If corticosteroids provide inadequate relief: Consider HA injection in shared decision-making

   • Discuss limited evidence
   • May provide longer duration than steroids (up to 24 weeks) 6
   • Cost is typically out-of-pocket

3. If mild-moderate OA and patient can afford it: Consider PRP

   • Avoid in severe OA
   • Understand conflicting guideline recommendations

4. Concurrent with any injection: Initiate surgical referral discussion

   • Do not delay referral until severe functional limitation
   • Age, obesity, and comorbidities should not be barriers 2

Common Pitfalls to Avoid

• Don't wait too long for surgical referral: The NICE guideline emphasizes referral should occur before prolonged functional limitation 2
• Don't use opioids/tramadol: The AAOS guideline explicitly states these should not be used due to increased adverse effects without consistent benefit 1
• Don't inject too frequently: Respect the 3-4 injections per year limit for corticosteroids 3
• Don't assume HA is worthless: While not routinely recommended, it may benefit select patients when other options have failed 5

The bottom line: Repeat corticosteroid injection is your evidence-based choice, but this patient is approaching or at the threshold for surgical evaluation.